BioTuesdays
Feature

diaDexus awaiting GSK’s darapladib pivotal results

By Len Zehr Positive data from GlaxoSmithKline’s two pivotal trials of its darapladib cardiovascular drug could provide a huge boost to the utilization of diaDexus’ (OTCQB:DDXS) PLAC test, which is being used on...

September 17, 2013
Feature

In conversation with Zoe Barry

By Len Zehr As founder and CEO of ZappRx, a consumer engagement company focused on improving the electronic prescription process, Zoe Barry began her career as an analyst at hedge fund, Dawson Capital, in New York...

September 10, 2013
Feature

Stereotaxis sees Japanese reimbursement by year end

By Len Zehr After receiving regulatory clearance in Japan of its Niobe Remote Magnetic Navigation system for cardiac ablations last March, Stereotaxis (NASDAQ:STXS) now expects to achieve reimbursement approval by the...

September 3, 2013
Feature

In conversation with Rudy Mazzocchi

By Len Zehr As president and CEO of closely-held ELENZA, Rudy Mazzocchi knows a thing or two about taking startups across the finish line. Among other things, he was the founder of eV3, which is now part of Covidien...

August 27, 2013
Feature

Galectin targets silent epidemic in liver fibrosis

By Len Zehr Fatty liver disease, or the accumulation of fat in liver cells, is a “silent epidemic,” says Dr. Peter Traber, president, CEO and chief medical officer of Galectin Therapeutics (NASDAQ:GALT). In an interview...

August 20, 2013
Feature

RedHill readying Phase 3 trials in Crohn’s

By Len Zehr With a PDUFA target date of Feb. 3, 2014 for its migraine drug, RHB-103, and NDA filing planned for the first quarter of 2014 for the anti-emetic drug, RHB-102, RedHill Biopharma (NASDAQ,:RDHL; TASE:RDHL) is...

August 13, 2013
Feature

Elite eyes home run in abuse-resistant technology

By Len Zehr After reinventing itself in 2011, Elite Pharmaceuticals (OTCBB:ELTP) has bounced back with a line of generic drugs and is banking on the development of abuse-resistant opioids and once-daily opioid products...

August 6, 2013
Feature

In conversation with Todd Wyche

By Len Zehr As CEO and a co-founder of Brinson Patrick Securities, Todd Wyche has championed the use and growth of at-the-market offerings (ATMs) for the past 17 years for REITs, energy companies and most recently...

July 2, 2013
Feature

Avivagen shifts to commercial mindset from R&D

By Len Zehr Cameron Groome, who moved into the executive suite at Avivagen (TSX-V:VIV) in March, has transformed the focus of the animal wellness company to a business and product development engine and away from an...

June 18, 2013
Feature

Oramed readies oral insulin study in U.S.

By Len Zehr Oramed Pharmaceuticals (NASDAQ:ORMP) is awaiting a decision from the FDA, possibly later this week, to conduct a sub-study of the safety of its oral insulin candidate, ORMD-0801, before proceeding to a...

May 7, 2013
Feature

Vaxil trial validates vaccine technology

By Len Zehr Results of a recent clinical trial of Vaxil Bio’s (TASE:VAXL) ImMucin cancer vaccine in patients with multiple myeloma has validated the company’s VaxHit technology by demonstrating safety and a strong...

April 23, 2013
Feature

OnPoint’s Big-Data Equals Big Opportunity

By Len Zehr OnPoint Medical Diagnostics (OTCQB:ONMD) is pioneering a “big-data” platform for delivering measurable, objective and automated quality assurance (QA) solutions for magnetic resonance imaging (MRI), with...

April 16, 2013
Feature

DURECT awaiting Pfizer meeting with FDA on Remoxy

By Len Zehr DURECT (NASDAQ:DRRX) has a lot riding on a meeting in late March between its marketing partner, Pfizer, and the FDA to discuss resubmitting a new drug application for its lead pain drug, Remoxy, as a tamper...

February 26, 2013
Feature

In conversation with Will Zerhouni

By Len Zehr As CEO of closely held i3 Analytics, Will Zerhouni founded the company on the belief that data analytics should be for everyone in biopharma, not just major players with deep pockets. As a former associate...

February 5, 2013
Feature

Prima BioMed to get key CVac data in second half

By Len Zehr After posting positive trends in interim data, Prima BioMed (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) is focusing on two final data readouts in the second half this year from a Phase 2b clinical trial of its...

January 29, 2013
Feature

Trimel in pre-NDA meeting with FDA next month

By Len Zehr Fresh from reporting positive Phase 3 results for its CompleoTRT intranasal gel for “Low T”, Trimel Pharmaceutics (TSX:TRL) plans to meet with the FDA in February to discuss its plans for filing a new drug...

January 15, 2013